Mutflash - Medizinische Argumentationen und Studiensammlungen
1.24K subscribers
11.4K photos
1.9K videos
255 files
10.9K links
Unser Hauptkanal:

https://t.me/Mutflash

P.s.: Leute die ohne eine vernünftige Grundlagenargumentation gegen Biom/ Virom argumentieren sind UNwillkommen!
Download Telegram
Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid Deliver

Branched-Tail Lipid Nanoparticles for Intravenous mRNA Delivery to Lung Immune, Endothelial, and Alveolar Cells in Mice

"Notably, ≈75% of the most efficacious LNPs were formulated with ionizable lipids containing branched, unsaturated tails. This is consistent with previous observations from our group and others.[9, 50, 54] Indeed, the COVID-19 mRNA vaccine lipids—Moderna's SM-102 and Acuitas’ ALC-0315—both include branched tails,[7, 55] and ongoing clinical trials are thought to be conducted using similarly branched lipids.[56] Regarding mechanism, the efficaciousness of branched tail lipids is likely facilitated by their enhanced cone-like structure that, when ionized and paired with anionic phospholipids in the endosomal membrane, more effectively disrupts the endosome for intracellular RNA release.[56-58]"

Die papers geben euch den Rest.
👍2
Off target toxicities and links with physicochemical properties of medicinal products, including antibiotics, oligonucleotides, lipid nanoparticles (with cationic and/or anionic charges). Data review suggests an emerging pattern

"This paper brings together the key off-target and/or non-specific toxicities that are, or have been, associated or linked to the physicochemical properties of compounds, especially those carrying positive or negative charges, including amphiphilic small molecules, proteins/peptides, oligonucleotides and lipids. Whilst charge alone cannot be explicitly linked to a certain toxicity, it is clear, that along with the general physicochemical attributes, the nature of the charge is an important contributory factor. In fact, and as noted by references that date back more than 20 years, the potential toxicities associated with physicochemical properties and inherent charge have had a negative influence on drug development for an extensive period. Lee et al., 2017 showed how primary amines were less promiscuous and less likely to induce off target toxicity than secondary or tertiary amines and it has been well established in many studies investigating structural relationships that lipophilicity can impact on increasing the risk of off target toxicity (Brown et al., 2020).

The information included in this paper was collated and extrapolated from published literature, generated by various laboratories, who have used different study designs and species. The aim of the paper is to show how physicochemical properties, in particular the charge, could influence a toxicity profile and to highlight an emerging pattern that suggests that there may be some commonality, which may be worth toxicologists working in the pharmaceutical industry to consider."

(...)

"Cationic or ionic charges can result in unwanted toxicity, and these toxicities are often discussed as singular events in the literature, such as, drug induced phospholipidosis of CAD’s or Histamine Release of Vancomycin (Aminoglycoside).

By collating noted off-target toxicities that are associated with physicochemical products (in particular charged products), while using published literature, an emerging pattern relating to the nature of their toxicities starts to appear, which we categorized under the following key headlines:

1) cytotoxicity/haemolysis;.

2) phospholipidosis type pathology/vacuolation;.

3) immune system related (e.g., hypersensitivity like findings).

Within these three main categories, toxicities can be further broken down into organ systems or specific endpoints (see Table 1). There are without doubt gaps in our understanding, in particular the mechanism, and not least, because this topic has understudied. Therefore, whilst it is of note that there is limited data available, and at this point it is not possible to pinpoint a single mechanism or provide a clear association, there is enough data to suggest there is a pattern emerging, which should be considered further in the future, and added to, as more data and research is published. We also noted that diagnostic terminology particularly in relation to immune-based/hypersensitivity diagnoses may not be harmonious across the literature and is another topic for further consideration, which may also provide further understanding and insight, particularly where there is evidence of overlay in cause and effect: for example: Histamine Release and CARPA- are these one in the same? The aim and key message from this paper is that there is a pattern to be followed and further understood, which is beyond the simple cationic/amphiphilic classification."

https://www.sciencedirect.com/science/article/abs/pii/S0378427423002242
"Vaccine stocks tumbled in the early U.S. cash session after Peter Marks—a top FDA regulator and pro-vaxxer—abruptly resigned on Friday.

Wall Street analysts view Marks' departure as a bearish signal for vaccine stocks, such as Moderna, Novavax, BioNTech, and others, which already face mounting headwinds, including a wave of layoffs expected at the Department of Health and Human Services.

Moderna puked at the open, down 12% in early trading, while the SPDR S&P Biotech ETF sank 2%. Other makers of vaccine stocks plunged, including Novavax -10% and BioNTech -5.8%.

Moderna shares are also down 95% from peak Covid highs."

https://www.zerohedge.com/markets/vaccine-stocks-tank-after-fda-biologics-head-abruptly-steps-down-era-rfk-jr
*leise seufz* Da ich mit immer argwöhnischeren Augen auf Methodikteile gucke, habe ich mittlerweile auch eine brutale Kritik an dem Kämmerer-Paper:

Hier ist der Methodikteil. fokussiert euch bitte genau auf meine Kritik ds-DNA/ RNA-DNA-HYBRID/ ssDNA: Ich lese hier NICHTS, was meine Verwirrung entwirrt?!

"Materials and Methods

Vaccine Lots

The following original and unopened BNT162b2 vaccine lots were used: FD7958 (monovalent Wuhan; expiry date October 2021), FE6975 (monovalent Wuhan; expiry date October 2021), EX8679 (monovalent Wuhan; expiry date August 2021), HD9869 (bivalent Wuhan/Omicron XBB1.5; expiry date October 2024). As positive control for the PCR reaction and mass spectrometry analysis, lot GH9715 (bivalent Wuhan/Omicron BA.4 and BA.5; expiry date June 2023) was used, because its contamination with the SV40 containing plasmid was proven already [25]. The vials were provided to us by the pharmacy in the manufacturer’s refrigerated state. They were unopened and always refrigerated during transport and storage.

Cell Line Experiments and ELISA

HEK293 cells were grown in a humidified incubator at 37 °C, 5% CO2. The cells used were from original stocks (Cell Lines Service GmbH, Eppenheim, Germany) regularly tested negative for mycoplasma and stored in aliquots in liquid nitrogen. Cells were thawed fresh prior to transfection experiments, cultured in 10 cm well dishes with DMEM with 10% fetal calf serum supplemented with 1% penicillin/streptomycin until confluency and transferred after trypsinization (0.05% trypsin/EDTA (Gibco #11500636) 3 min 37 °C) to new wells, according to the experimental set up described below.

For all transfection experiments, the vials with the monovalent mRNA were pre-diluted 1:5 with sterile RNase-free phosphate-buffered saline (PBS) to the clinical concentration, according to the manufacturer. The bivalent vials were not pre-diluted since the clinical concentration was already present. For ELISA, 12-well plates with 80% cell density and a medium volume of 1 ml each were transfected with 1/12 (25 µl) of a clinical dose of a vial and cells and media were harvested at time points day 1, day 3, day 5, and day 7. Untransfected cells at day 7 served as negative control. For protein analysis, cells were washed twice in sterile phosphate-buffered saline (PBS) after the respective incubation time (see above), lysed in lysis buffer (25 mM Tris, 150 mM NaCl, 1% Triton-X-100, 1% NP40, pH 7.6) and the spike protein level was determined in the protein supernatant and the media using a commercially available high-sensitive S-Plex SARS-CoV-2 Spike ELISA assay (Mesoscale Discovery K150ADJS).

Immunohistochemistry

Immunohistochemistry was performed using a standard protocol. In brief, 60% dense cells on 24-well plates were transfected with 12.5 µl of a clinical dose per well in 200 µl medium. After 4h of incubation, the cells were washed twice with sterile PBS and 500 µl fresh growing media were applied to the wells. 24h after the start of transfection, cells were harvested, fixed in 4% buffered paraformaldehyde, embedded in 2% agarose/water and dehydrated using a standard dehydration protocol for biopsy samples. Thereafter, the agarose blocks were embedded in paraffin and cut. Sections were placed on Superfrost slides, dewaxed twice with xylene and rehydrated in a graded series of ethanol and in distilled water. After rehydration and antigen retrieval (ACD biotechne #322000, 15 min steamer), the slides were permeabilized (0.3% Triton-X-100/PBST), treated with peroxide suppressor (Thermo Scientific #35000), and blocked in PBS with 1% goat serum, 1% BSA, 0.1% Triton-X-100, and 0.05% Tween-20. Then, the slides were incubated with the rabbit polyclonal antibody against SARS-CoV-2 spike protein (S1-subunit; ProSci #9083) overnight at 4 °C, washed in PBS, and incubated with anti-rabbit poly-HRP antibody (Invitrogen #32260) for 30 min at room temperature. Protein detection was performed using permanent HRP Green Kit (Zytomed), counterstained in hematoxylin, and embedded in RotiHistol II Kit.
*leise seufz* Da ich mit immer argwöhnischeren Augen auf Methodikteile gucke, habe ich mittlerweile auch eine brutale Kritik an dem Kämmerer-Paper:

DNA and RNA Quantification

One clinical dose of each vial was diluted 1:10 with sterile RNase-free PBS supplemented with 1% Triton-X-100. For quantification of RNA, 10 µl of the diluted clinical dose was applied on a black 96-well plate in triplicates and treated with Qubit RNA High Sensitivity Assay (Invitrogen #Q32852). For quantification of dsDNA, 10 µl of the diluted clinical dose was applied on a black 96-well plate in triplicates and treated with Qubit dsDNA High Sensitivity Assay (Invitrogen #Q33230), Quanti-iT Pico Green dsDNA Assay (Invitrogen #P7589), or AccuBlue High Sensitivity dsDNA Assay (Biotium #31006-T). RNase A (final concentration 50 µg/ml, DNase-free Monarch RNase A #T3018L) treatment was performed at 37 °C for 30 min. Signals of all assays were quantified with a standard plate reader at excitation 483 nm and emission 530 nm. There was no signal overlap between excitation and emission wavelengths for the respective fluorophores used in the kits. We measured the amount of DNA and RNA (Figure 1 A-C) and calculated the DNA/RNA ratio relative to 1 mg RNA. These ratios were put in relation to the EMA regulation of 0.33 mg dsDNA per 1 mg RNA. From this, we obtained the increase factor in Table 3 and Figure 1D.

Polymerase Chain Reaction (PCR)

To isolate plasmid DNA from cells, 6 cm dishes with cells at 80% density were transfected with half of a clinical dose of each vial (150 µl /well) added to 1ml of medium. Untransfected cells served as negative control. After 6h, cells were harvested, washed twice in PBS, and plasmid DNA was purified (Gene Jet Plasmid Mini Kit). Aliquots of 1-10 ng DNA were loaded into each PCR reaction.

To determine the DNA content in the vials, one clinical dose of each vial was diluted 1:10 in EB buffer (10 mM Tris-HCl, pH 8.5) supplemented with 1% Triton-X-100. For the PCR reaction, primers were designed using PrimerBlast and ordered via Eurofins Genomics, dissolved in nuclease-free water and used as final concentration of 0.2 mM. For the location of the primer pairs in relation to the expression vector, see Figure 3A. 1 µl of the diluted solution was used as template and processed according to standard Taq polymerase protocol (94 °C 30 sec, 60 °C 30 sec, 72 °C, 30 sec, 38 cycles) using Taq DNA polymerase with Standard Taq Buffer (New England Biolabs #M0273S). Nuclease-free water served as negative control. A vial containing batch GH9715 was used as a positive control, as plasmid DNA from this batch was already isolated and sequenced [21,22] and confirmed to refer to the plasmid sequence BNT162b2 (GenBank PP544445.1, GenBank PP544446.1, GenBank MQ287666.1 representing sequence 16 from patent WO2021214204) published by BioNTech. The primers applied are described in Table 1. Finally, the PCR reactions were loaded onto a 2% agarose gel with ethidium bromide in standard TAE buffer (running time ~ 1h; 100V). Gene Ruler DNA-Ladder Mix (Thermo Scientific #SM0331) was used as DNA marker.


Table 1.

Characterization of the primers used for PCR.

EV Isolation and Secretome Concentration

Cells were grown in 6 cm dishes to 80% density and transfected with half of a clinical dose (150 µl) of the bivalent lot GH9750 added to 1 ml of medium. Untransfected cells served as negative control. After 6h, cells were washed and media was changed to 5 ml fresh media. After further 18h, media were collected and cells were washed twice in PBS, harvested and further processed for mass spectrometry.
*leise seufz* Da ich mit immer argwöhnischeren Augen auf Methodikteile gucke, habe ich mittlerweile auch eine brutale Kritik an dem Kämmerer-Paper:

EV isolation was performed as previously reported using the Vn-96 peptide capture method that precipitates EVs via binding to HSPs at the EV surface [28,29]. In brief, 20 µl of the VN-96 peptide (Microvesicle Enrichment kit, New England Peptide, #W1073-2, USA) was added to the cell conditioned medium (2 ml) obtained from HEK293 (un)transfected cells, and incubated on a rotation wheel for 1h at room temperature. EVs were isolated after centrifugation for 15 min at 16,000 xg at 4 °C. The supernatant (soluble secretome) was collected into a new tube and concentrated using a 3kDa MWCO filter (Merck, Amsterdam, The Netherlands, cat. no. UFC500396). EV pellet was washed once with 1 ml PBS (4 °C) containing PIC (complete Mini EDTA-free, #11836153001 Roche, Germany).

Sample Preparation For Proteomics

Sample preparation for proteomics was performed as previously described [30,31]. To this end, an aliquot of the cell pellet suspension in PBS, corresponding to ~25 mg of protein was lysed in 30 ml LDS sample buffer (containing 10% dithiothreitol, Life Technologies, Carlsbad, CA, cat. no. NP0008), 20 ml soluble secretome was lysed with 10 ml 3x LDS sample buffer, and EV pellet was solubilized in 30 µl 1x LDS sample buffer, all at room temperature. Subsequently, samples were heated for 5 min at 99oC and sonicated (3x 20 sec) and fractionated using gel electrophoresis in precast Bis-Tris 4-12% gradient gels using the NuPAGE SDS-PAGE system (Invitrogen, Carlsbad, CA) at room temperature. Following electrophoresis, gels were fixed in 50% ethanol / 3% phosphoric acid (Merck, Switzerland) solution and stained overnight with Coomassie Brilliant Blue R-250 (Thermo Scientific, UK) at room temperature. Subsequently, the gels were washed with 25 ml 50 mM ammonium bicarbonate (Fluka, Seelze, Germany) and with 25 ml 50 mM ammonium bicarbonate with 50% acetonitrile (Biosolve BV, Valkenswaard, The Netherlands). Proteins were reduced and alkylated by incubating the whole gel in 25 ml dithiotreitol for 1h at 56 °C and 25 ml 55 mM iodoacetamide (Sigma-Aldrich, USA) for 45 min at room temperature, respectively. Gel lanes were cut into 3 bands and each band was cut into ~1 mm3 cubes. The gel cubes from each band were dried in a SpeedVac centrifugal evaporator for 10 min at 50 oC and incubated ~100-200 ml (enough to cover) with 6.25 ng/ml sequencing grade modified trypsin (Promega, Madison, USA) overnight at room temperature. The peptides from each gel band were extracted with 100-150 ml 1% formic acid and two times with 100-150 ml 5% formic acid / 50% acetonitrile, lyophilized and stored at -20 °C until LC-MS/MS analysis.

Mass Spectrometry-Based Proteomics
*leise seufz* Da ich mit immer argwöhnischeren Augen auf Methodikteile gucke, habe ich mittlerweile auch eine brutale Kritik an dem Kämmerer-Paper:

Label-free proteomics of lysates, EV, and soluble secretome samples was performed using an Evosep chromatography system coupled to a TimsTOF-HT MS/MS system (Bruker, Germany). Peptides (600 ng / sample as determined by Nanodrop) were dissolved in 0.1% FA and loaded on Evotips (Evosep, Denmark) as per manufacturer protocol. Peptides were separated via nanoflow reversed-phase liquid chromatography using standardized gradients on an Evosep One liquid chromatography system (Evosep, Denmark) with 0.1% FA and 0.1% FA / 99.9% ACN as the mobile phases at room temperature. The 30 samples per day (SPD) method was used in combination with a 15 cm x 150 μm reverse-phase column packed with 1.5 μm C18-beads (Bruker Daltonics) connected to a 20 μm ID fused silica emitter (Bruker Daltonics). Peptides were introduced to a TimsTOF HT (Bruker Daltonics) using a nano-electrospray ion source (Captive spray source, Bruker Daltonics) with spray voltage set to 1500 V. The TimsTOF HT was running in DDA-PASEF mode with a ramp time set to 100 ms and ten PASEF scans were acquired per topN acquisition cycle, resulting in a cycle time of 1.16 s. Precursors with a mass range from 100 m/z to 1700 m/z, ion mobility range from 1.5 to 0.7 Vs cm−2, and charge states from 0 (unassigned) to 5+ were analyzed. The intensity threshold was set to 2,500 arbitrary units (a.u.) and target value to 20,000 a.u. Precursors that reached this target value or full scheduling capacity were excluded for 0.4 min. Single charged precursors were filtered out based on their m/z-ion mobility position. Precursors with a mass below 700 Da were isolated with a quadrupole isolation width of 2 Th, precursors above 700 Da with a width of 3 Th. Collision energy was linearly decreased from 59 eV at 1.6 Vs cm-2 to 20 eV at 0.6 Vs cm-2. For all experiments, the ion mobility dimension was calibrated linearly using three selected ions of the Agilent ESI LC/MS Tuning Mix [m/z, 1/K0: (322.0481, 0.7318 Vs cm−2), (622.0289, 0.9848 Vs cm−2), (922.0097, 1.1895 Vs cm−2)].

MS/MS spectra were searched using MaxQuant 2.3.1.0 against the reviewed human proteome (Uniprot, March 2023, 42420 entries including isoforms) and the sequences of the Moderna mRNA1273 expression vector, Pfizer bivalent expression vector BNT162b2 and the severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1 spike protein sequence, plus their ribosomally frameshifted translation products. Enzyme specificity was set to trypsin, and up to two missed cleavages were allowed. Cysteine carbamidomethylation (Cys, +57.021464 Da) was treated as fixed modification, and methionine oxidation (Met, +15.994915 Da) and N-terminal acetylation (N-terminal, +42.010565 Da) as variable modifications. Peptide and protein identifications were filtered at an FDR of 1% using the decoy database strategy. The minimal peptide length was 7 amino acids. Proteins that could not be differentiated based on MS/MS spectra alone were grouped into protein groups (default MaxQuant settings). Searches were performed with the label-free quantification option selected. Proteins were quantified by spectral counting [32]."

https://publichealthpolicyjournal.com/biontech-rna-based-covid-19-injections-contain-large-amounts-of-residual-dna-including-an-sv40-promoter-enhancer-sequence/?currency=USD#methods

Vllt. kann mir ja jemand erklären, wie diese Kombi ssDNA, hybride DNA-RNA und dsRNA differenzieren kann, wenn ich 100 Prozent N1-Methylpseudo-U in der RNA habe?! Weder die RNasen werden komplett verdauen. Noch die Farbstoffe wirklich zuverlässig binden. Alles - was ich nachher sehe, sind DNA-RNA-Verhältnisse in einer relativ korrekten Verhältnisangabe. Aber ich kann davon UNMÖGLICH auf die DNA-Struktur schlussfolgern.

Da ich jedoch bei DNA komplett raus bin und es nur ganz rudimentär verstehe:
RNA:DNA hybrids in the human genome have distinctive nucleotide characteristics, chromatin composition, and transcriptional relationships

https://epigeneticsandchromatin.biomedcentral.com/articles/10.1186/s13072-015-0040-6

Falls ihr versteht, WARUM das so relevant ist, wisst ihr auch, wieso ich immer weniger Vertrauen in irgendwen außerhalb meiner hauseigenen Denkfabrik habe!

Sources, resolution and physiological relevance of R-loops and RNA–DNA hybrids

https://www.nature.com/articles/s41580-022-00474-x

The dark side of RNA:DNA hybrids

https://www.sciencedirect.com/science/article/abs/pii/S1383574219300948

Der Methodikteil ist sehr aufschlussreich: DRIP-Sequ + RNase H + S1 Nuklease

Wenn es präziser sein soll würden sich Cryo-EM (Cryo-ET) oder TEM anbieten.
👍2
Wenn ich Frau Prof. Kämmerer (vor der ich tiefsten Respekt habe) fragen könnte, würde ich es so ausdrücken:

Frage: Wie kommen Sie auf die Annahme von ausschließlich DS-plasmider DNA? Ich sehe in KEINER Publikation einen plausiblen Nachweis dies als exklusive DNA-Möglichkeit zu charakterisieren und ss, sowie hybride RNA-DNA zu exkludieren?

Um darauf schlussfolgern zu können, hätten Cryo-EM oder vergleichbare Methodiken zur Charakterisierung angewendet werden müssen. Sämtliche nachlesbaren Methodiken werden an 2 Fakten scheitern: RNase Verdau mit 100 Prozent N1-Methylpseudo-U und fehlende Bestätigung via DNase 1 beispielsweise. (Noch besser: DRIP-Sequ + RNase H + S1 Nuklease um nach - wahrscheinlich vorhandenen - Hybriden zu schauen. Und auch hier ist das RNA-Verdauproblem gegeben.)
Forwarded from Dr. Shankara Chetty
Media is too big
VIEW IN TELEGRAM
‘A case of battery:’ Schools forcibly jabbed children ‘against their will’ with the COVID-19 shot + without parental consent.

Now, one mom is getting her day in court after the North Carolina Supreme Court ruled in her favor to sue the school for lack of informed consent.

Join ➡️ @ShankaraChetty